• 云顶集团(中国)

    Global
    关于云顶集团(中国)

    致力于纳米抗体创新药物研发

    关于云顶集团(中国)
    科研论文
    截止现在，云顶集团(中国)生物研发团队在具有重要影响力的期刊上发表研究论文多篇。
    2023-11-06
    TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
    发表于:J Nanobiotechnology. 2023 Nov 6;21(1):410
    查看更多内容
    2023-09-21
    Identification and Characterization of a Novel Nanobody Against Human CTGF to Reveal Its Antifibrotic Effect in an in vitro Model of Liver Fibrosis
    发表于:Int J Nanomedicine. 2023 Sep 21;18:5407-5422
    查看更多内容
    2022-11-19
    Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma
    发表于:Respiratory Research. 2022 Nov 19;23(1):316
    查看更多内容
    2022-10-24
    Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein
    发表于:Cells. 2022 Oct 24;11(21):3355
    查看更多内容
    2022-10-03
    Atomically dispersed Mn boosting photoelectrochemical SARS-CoV-2 spike protein immunosensing on carbon nitride
    发表于:Journal of Environmental Chemical Engineering. 2022 Dec;10(6):108697
    查看更多内容
    2022-07-22
    Evaluation of SARS-CoV-2-neutralizing Nanobody Using Virus Receptor Binding Domain Administered Model Mice-Research-2022
    发表于:Research (Wash D C). 2022 Jul 22;2022:9864089
    查看更多内容
    总计 24 1234